全球感染性疾病治疗市场分析报告.ppt

,MARKET RESEARCH REPORT,INFECTIOUS DISEASE TREATMENTS:,GLOBAL MARKETS,PHM061A,Peggy Lehr,Project Analyst,BCC Research,35 Walnut Street,Wellesley,MA 02481,Phone:866-285-7215(sales),Web Address:,E-mail:,ISBN:1-59623-590-X,ii,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,ABOUT BCC,BCC Research is a leading information resource producing high-quality market research reports,newsletters,and conferences.BCCs information products explore major market,economic,scientific,and technological developments for business leaders in industrial,pharmaceutical,and hightechnology organizations.Industry analysis and market forecasts for advanced materials,high-techsystems and components,nanotechnology and novel processing methods are at the forefront of thecompanys expertise.For more than 35 years,BCCs market analysis has provided businesses withthe insight needed to make intelligent and strategic business decisions.BCC Research is a unit ofEli Research,which is based in Durham,N.C.CONDITIONS OF PURCHASE,The purchase of the bound or electronic copy of this report constitutes a contractual agreementbetween BCC Research and the purchaser.This report is intended for use solely by the person whomade the purchase.The report and its contents are not to be made available to other persons,autonomous divisions,foreign subsidiaries of the same company,or other companies.Reproductionof any material in this report is strictly forbidden without written permission of the publisher.Inturn,BCC Research will regard the identity of the reports purchaser as confidential.,ADDITIONAL COPIES,Additional bound copies of this report,intended for use by the operating division for which the first copyis purchased,may be obtained from BCC at discounted prices.Additional bound copy prices do not applyto reports purchased for use at separate locations.Licenses for use of electronic copies by additionalpersons or locations are available.Please call BCC for pricing.,CUSTOM ANALYSES,BCC provides custom research studies tailored to our clients needs in areas related to the subjectresearch material,but perhaps not covered in detail in this report.Please contact BCC regarding theterms and conditions of such services.,DISCLAIMER,This publication provides informative material of a professional nature.It does not constitutemanagerial,legal or accounting advice,nor should it serve as a corporate policy guide,laboratorymanual or an endorsement of any product.This information is intended to be as accurate as possible atthe time of publication,but BCC Inc.assumes no responsibility for any losses or damages that mightresult because of reliance on this material.,Copyright 2009 by BCC Research Wellesley,MA 02481,Reproduction of any material in this report is strictly forbidden without express permission of thePublisher.,To receive a complete catalog of BCC studies,please visit our Web site at,APRIL 2010,Copyright BCC Research,Wellesley,MA USA,Web:,iii,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,CHAPTER ONE:INTRODUCTION.1STUDY GOALS AND OBJECTIVES.1REASONS FOR DOING THE STUDY.1SCOPE OF REPORT.2INTENDED AUDIENCE.2METHODOLOGIES AND INFORMATION SOURCES.2ANALYST CREDENTIALS.2RELATED BCC REPORTS.2BCC ONLINE SERVICES.3DISCLAIMER.3CHAPTER TWO:SUMMARY.4SUMMARY.4SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASETREATMENTS,THROUGH 2014($BILLIONS).5SUMMARY FIGURE GLOBAL MARKET FOR INFECTIOUS DISEASETREATMENTS,2008-2014($BILLIONS).5CHAPTER THREE:OVERVIEW.6,TABLE 1 SELECTED MAJOR INFECTIOUS DISEASES,WORLDWIDE,2006(NUMBER OF CASES,ANNUALLY).6TABLE 1(CONTINUED).7HISTORICAL IMPACT OF INFECTIOUS DISEASES.7LINKING INFECTIOUS DISEASE TO CANCER.8TRANSMISSION OF INFECTIOUS DISEASES.8TREATMENTS FOR INFECTIOUS DISEASES.8PREVENTION.8VACCINATION.9FIGURE 1 PERCENT OF PREVENTABLE CHILDHOOD DEATHS,WITH VACCINATION,2002(%).9FIGURE 1(CONTINUED).10TABLE 2 MAJOR MANUFACTURERS OF VACCINES FOR,INFECTIOUS DISEASES,2008.10,TABLE 3 ESTIMATED VACCINE SALES FOR INFECTIOUS,DISEASES,BY MANUFACTURER,2008(%/$MILLIONS).11,TABLE 4 PROJECTED SALES OF VACCINES TO TREATINFECTIOUS DISEASES WORLDWIDE,THROUGH 2014($,BILLIONS).12TABLE 5 SELECTED TREATMENT MODALITIES,BY DISEASE ANDTYPE OF PRODUCT.12,MONITORING AND SURVEILLANCE.13,Copyright BCC Research,Wellesley,MA USA,Web:,iv,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,CURRENT IMPACT OF INFECTIOUS DISEASES.13TABLE 6 TOP 10 CAUSES OF DEATH,BY INCOME GROUP,2004(%).13TABLE 6(CONTINUED).14,ANTIBIOTIC-RESISTANT ORGANISMS.14IMPLICATIONS OF CLIMATE-CHANGE ON INFECTIOUSDISEASES.14KEY DRIVERS OF INFECTIOUS DISEASE PRODUCT MARKET.15KEY OBSTACLES IN THE INFECTIOUS DISEASE PRODUCT,MARKET.15OPPORTUNITIES TO FIGHT INFECTIOUS DISEASES.16OPPORTUNITIES TO FIGHT(CONTINUED).17CHAPTER FOUR:THE GLOBAL STATE OF INFECTIOUS DISEASE,CONTROL AND TREATMENT.18FACTORS IN THE EMERGENCE OF INFECTIONS.18HUMAN DEMOGRAPHICS AND BEHAVIOR.18TECHNOLOGY.18ECONOMIC DEVELOPMENT AND LAND USE.19INTERNATIONAL TRAVEL.19MICROBIAL ADAPTATION.19TABLE 7 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL.20,PUBLIC HEALTH MEASURES.20GLOBAL IMPLICATIONS OF INFECTIOUS DISEASES.20REGIONAL TRENDS.21,Sub-Saharan Africa.21Asia and the Pacific.21The Former Soviet Union and Eastern Europe.21Latin America.21Middle East and North Africa.21Western Europe.22GLOBAL ECONOMIC,SOCIAL,AND POLITICAL IMPACT.22ECONOMIC COSTS.22SOCIAL COSTS.23POLITICAL IMPACT.23IMPLICATIONS OF INFECTIOUS DISEASE IN THE U.S.23HIV/AIDS.23HEPATITIS C.24TUBERCULOSIS.24INFLUENZA.24ANTIBIOTIC-RESISTANT PATHOGENS.24FOOD-BORNE ILLNESSES.24,Copyright BCC Research,Wellesley,MA USA,Web:,v,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,INFECTIOUS DISEASES ACQUIRED OUTSIDE OF THE U.S.25EMERGING INFECTIOUS DISEASES.25EMERGING BACTERIAL INFECTIOUS DISEASES.25EMERGING VIRAL INFECTIOUS DISEASES.25Metapneumoviruses.26HenipavirusNipah,Hendra.26PRION DISEASE.26CREATING TREATMENTS FOR INFECTIOUS DISEASE.27CREATING DRUG TREATMENTS.27TABLE 8 PROCESS OF CREATING DRUG TREATMENTS.27TABLE 8(CONTINUED).28,CREATING VACCINES.29Creating Vaccines(Continued).30TABLE 9 TOP FIVE VACCINE-PRODUCING COMPANIES,2009.31,ACQUISITIONS AMONG MANUFACTURERS OF,INFECTIOUS DISEASE PRODUCTS.31TABLE 10 SELECTED ACQUISITIONS AMONG INFECTIOUS,DISEASE DRUG AND VACCINE MANUFACTURERS,2006-2010.31TABLE 10(CONTINUED).32CHAPTER FIVE:BACTERIAL INFECTIOUS DISEASES.33,TABLE 11 SELECTED BACTERIAL INFECTIOUS DISEASES AND,THE NUMBER OF CASES IN HUMANS.33TABLE 11(CONTINUED).34TABLE 12 PROJECTED MARKET FOR ANTIBACTERIAL,TREATMENTS THROUGH 2014($MILLIONS).34THE GLOBAL ANTIBACTERIAL DRUG MARKET.35TREATMENTS.35,FIGURE 2 LEADING MANUFACTURERS OF ANTIBACTERIAL,DRUGS,WITH APPROXIMATE MARKET SHARE,2008(%).35FIGURE 2(CONTINUED).36TABLE 13 MAJOR MANUFACTURERS OF ANTIBACTERIALS ANDTHEIR PRODUCTS,2009.36MAJOR INFECTIOUS BACTERIAL DISEASES.37BACTERIAL DIARRHEAL DISEASES.37Cholera.37,Frequency.37Treatment.38Clostridium Difficile.38,Treatments under Development.38Campylobacter.39,Copyright BCC Research,Wellesley,MA USA,Web:,vi,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,Treatment.39EMERGING FOOD-BORNE/WATER-BORNE ILLNESSES.39,TABLE 14 CURRENTLY AVAILABLE TREATMENTS FOR,SALMONELLA AND THEIR MANUFACTURERS.40,HAEMOPHILUS INFLUENZAE B(HIB).41Vaccination.41TABLE 15 PROJECTED MARKET FOR HIB VACCINE,THROUGH,2014($MILLIONS).42,PNEUMONIA.42Current Treatment.42Vaccines.42TABLE 16 PROJECTED REVENUES FROM VACCINES ANDMEDICATIONS TO TREAT PNEUMONIA,THROUGH 2014($,MILLIONS).43,SEXUALLY TRANSMITTED DISEASES.43Chlamydia.43TABLE 17 PRIMARY ANTIBIOTICS TO TREAT CHLAMYDIA.44,Emerging Treatment.44Gonorrhea.44TABLE 18 PRIMARY ANTIBIOTICS TO TREAT GONORRHEA.45,Emerging Treatment.45Syphilis.45Chancroid.46STAPHYLOCOCCAL INFECTIONS.46,Emerging Treatments.47,Dalbavancin.47Telavancin.47Oritavancin.47Ceftobiprole.48Ceftaroline.48TUBERCULOSIS.48TABLE 19 NUMBER OF CASES OF TB ANNUALLY,BY COUNTRY,2007.49,Frequency.49,United States.49European Region.50Drug-resistant Strains.50Current Treatments.50TABLE 20 PROJECTED GLOBAL REVENUES FOR TB DRUGS,THROUGH 2014($MILLIONS).51,Copyright BCC Research,Wellesley,MA USA,Web:,vii,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,TABLE 21 CURRENTLY AVAILABLE TREATMENTS FOR TB ANDTHEIR MANUFACTURERS.51,Emerging Treatments.51URINARY TRACT INFECTIONS.52TABLE 22 CURRENTLY AVAILABLE TREATMENTS FOR UTIS ANDTHEIR MANUFACTURERS.53,EMERGING TREATMENTS.53,Bacterial Interference.53Bacteriophage Therapy.53,Bacteriophage Therapy(Continued).54Bacterial Vaccines.55,Cationic Peptides.55Cyclic D,L-a-Peptides.56CHAPTER SIX:FUNGAL INFECTIOUS DISEASES.57OPPORTUNISTIC FUNGAL INFECTIONS.57PRIMARY FUNGAL INFECTIONS.57FUNGAL INFECTIOUS DISEASES.58TABLE 23 PROJECTED COST OF ANTIFUNGAL AGENTS TO TREATFUNGAL INFECTIONS,THROUGH 2014($BILLIONS).58,FIGURE 3 MARKET SHARE OF COMPANIES INVOLVED IN THE,TREATMENT OF FUNGAL INFECTIONS,2009(%).59,CANDIDIASIS.59Causes of Candidiasis.60Frequency.60Treatment.61TABLE 24 CURRENT MEDICATIONS FOR CANDIDIASIS,2009.61TABLE 24(CONTINUED).62,Future Market.62ASPERGILLOSIS.62TABLE 25 CURRENT MEDICATIONS FOR ASPERGILLOSIS,2009.63,COCCIDIOIDOMYCOSIS.63,Frequency.63Treatment.64,TABLE 26 CURRENT MEDICATIONS FOR COCCIDIODOMYCOSIS,2009.64,CRYPTOCOCCOSIS.64,Frequency.65Treatment.65TABLE 27 CURRENT MEDICATIONS FOR CRYPTOCOCCOSIS,2009.65,MUCORMYCOSIS.65,Copyright BCC Research,Wellesley,MA USA,Web:,viii,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,Frequency.66Treatment.66TABLE 28 CURRENT MEDICATIONS FOR MUCORMYCOSIS,2009.66,PARACOCCIDIOIDOMYCOSIS.67,Frequency.67Treatment.67,TABLE 29 CURRENT MEDICATIONS FOR,PARACOCCIDIOIDOMYCOSIS,2009.67,PNEUMOCYSTIS CARINII.68Frequency.68Treatment.68,TABLE 30 CURRENT MEDICATIONS FOR PNEUMOCYSTIS CARNII,2009.69SPOROTYRICHOSIS.69,Treatment.69TABLE 31 CURRENT MEDICATIONS FOR SPOROTYRICHOSIS,2009.69,TRICHOSPORON INFECTIONS.70,Frequency.70Treatment.70TABLE 32 CURRENT MEDICATIONS FOR TRICHOSPORON,INFECTIONS,2009.70ZYGOMYCOSIS.71,Frequency.71Treatment.71TABLE 33 CURRENT MEDICATIONS FOR ZYGOMYCOSIS,2009.71CHAPTER SEVEN:VIRAL INFECTIOUS DISEASE.72MAJOR DISEASES.72RESEARCH FUNDING.72TABLE 34 GLOBAL PROJECTIONS FOR VIRAL INFECTIOUS,DISEASE TREATMENTS,THROUGH 2014($MILLIONS).73HIV/AIDS.73,TABLE 35 PROJECTED GLOBAL MARKET FOR HIV DRUGS,THROUGH 2014($MILLIONS).74SHIFTING PRIORITIES.74TABLE 36 10 LEADING GLOBAL HIV MANUFACTURERS,2010.74FIGURE 4 MARKET SHARE FOR TOP MANUFACTURERS OF HIVTREATMENTS,2009(%).75,EMERGING TREATMENTS.76,Gilead Sciences.76Merck.76,Copyright BCC Research,Wellesley,MA USA,Web:,ix,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,ViiV Healthcare.76Tibotec.76,TMC 278.77COMMON PEDIATRIC VIRAL INFECTIONS.77POLIOMYELITIS.77DIPHTHERIA,TETANUS,PERTUSSIS(DTP).78TABLE 37 PROJECTIONS FOR DTP,POLIO,HIB COMBINATION,VACCINE SALES,THROUGH 2014($MILLIONS).79,MEASLES,MUMPS,RUBELLA.79Measles.79Mumps.80Rubella.80,TABLE 38 PROJECTED GLOBAL REVENUES FROM MMR VACCINE,THROUGH 2014($MILLIONS).81CROUP.81OTITIS MEDIA(EAR INFECTIONS).81,Causes of Otitis Media.82Treatment.82TABLE 39 PROJECTED COSTS OF OTITIS MEDIA TREATMENTS,THROUGH 2014($MILLIONS).82,Pharmacological Intervention.82Surgical Intervention.83TABLE 40 GLOBAL SURGICAL COSTS FOR MYRINGOTOMY IN,PEDIATRIC PATIENTS,THROUGH 2014($MILLIONS).83,TABLE 41 GLOBAL SURGICAL COSTS FOR,TONSILLECTOMY/ADENOIDECTOMY IN PEDIATRIC PATIENTS,THROUGH 2014($MILLIONS).84INFLUENZA.84INFLUENZA TREATMENTS.85TABLE 42 PROJECTED GLOBAL MARKET FOR INFLUENZA,TREATMENTS,THROUGH 2014($MILLIONS).85,FIGURE 5 ESTIMATED MARKET SHARE OF COMPANIES IN,INFLUENZA TREATMENT MARKET,2009(%).86,EMERGING TREATMENTS.86HEPATITIS.87TABLE 43 HEPATITIS CHARACTERISTICS,BY TYPE.87TABLE 43(CONTINUED).88TABLE 44 VACCINES AND MEDICATIONS FOR THE TREATMENTOF HEPATITIS,2010.88TABLE 44(CONTINUED).89,Copyright BCC Research,Wellesley,MA USA,Web:,x,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,TABLE 45 PROJECTED MARKET FOR HEPATITIS MEDICATIONSAND VACCINES,THROUGH 2014($MILLIONS).90,HEPATITIS A.90,TABLE 46 PROJECTED REVENUE FROM HEPATITIS AVACCINATION AND TREATMENTS,THROUGH 2014($,MILLIONS).91,HEPATITIS B.91,TABLE 47 PROJECTED REVENUE FROM HEPATITIS BVACCINATION AND TREATMENTS,THROUGH 2014($,MILLIONS).92,Emerging Treatments.92HEPATITIS C.92,TABLE 48 PROJECTED REVENUE FROM HEPATITIS C,TREATMENTS,THROUGH 2014($MILLIONS).93FIGURE 6 MARKET SHARES FOR HEPATITIS C TREATMENTS,2010(%).93FIGURE 6(CONTINUED).94,Emerging Treatments.94HERPES VIRUSES.94TABLE 49 HERPES VIRUSES THAT INFECT HUMANS.94TABLE 50 PROJECTED MARKET FOR HERPES SIMPLEX VIRUS,MEDICATIONS,THROUGH 2014($MILLIONS).95,HERPES SIMPLEX VIRUS TYPE 1(HSV-1).95HERPES SIMPLEX VIRUS TYPE 2(HSV-2).95Prevalence.96Emerging Treatment.96,Chiron.96GlaxoSmithKline.97Xenova/GlaxoSmithKline.97Avant Immunotherapeutics.97EPSTEIN-BARR VIRUS.98HUMAN HERPES VIRUS 6.98HUMAN HERPES VIRUS 8.98EMERGING HERPES TREATMENTS.98NanoViricides,Inc.98Cytogenix.99Alnylam Pharmaceuticals,Inc.99VARICELLA VIRUSES.99CHICKENPOX.99SHINGLES.100,Copyright BCC Research,Wellesley,MA USA,Web:,xi,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,TABLE 51 PROJECTED MARKET FOR VARICELLA VACCINES,THROUGH 2014($MILLIONS).101ENTEROVIRUSES.101COXSACKIE VIRUSES.101CREUTZFELDT-JAKOB DISEASE(CJD).102EMERGING TREATMENTS.102,Quinacrine.102Pentosan Polysulphate(PPS).103OPPORTUNISTIC VIRAL INFECTIONS.103CYTOMEGALOVIRUS.103,Current Treatments.104TABLE 52 CURRENT TREATMENT OPTIONS FOR CMV,2009.104,KAPOSIS SARCOMA(KS).104HEMORRHAGIC FEVERS.105ARENAVIRUSES.106BUNYAVIRUSES.106FILOVIRUSES.106FLAVIVIRUSES.107,Frequency.107Current Treatment.108HUMAN PAPILLOMAVIRUS(HPV).108TREATMENT.108,TABLE 53 PROJECTED MARKET FOR HPV TREATMENTS,THROUGH 2014($MILLIONS).109,EMERGING TREATMENTS.109UPPER RESPIRATORY VIRUSES.109COMMON COLD.109SINUSITOSIS.110RESPIRATORY SYNCYTIAL VIRUS(RSV).110TABLE 54 CURRENT TREATMENTS FOR RSV.111TABLE 55 PROJECTED MARKET FOR RSV TREATMENTS,THROUGH 2014($MILLIONS).111,Emerging Treatments.112,Arrow Therapeutics.112Alnylam Pharmaceuticals.112AstraZeneca/MedImmune.112ROTAVIRUS.113GLOBAL IMPACT.114TREATMENTS.114ROTATEQ.114ROTARIX.114,Copyright BCC Research,Wellesley,MA USA,Web:,xii,PHM061A Infectious Disease Treatments:Global Markets,TABLE OF CONTENTS,TABLE 56 GLOBAL REVENUES FOR PEDIATRIC ROTAVIRUS,VACCINES,THROUGH 2014($MILLIONS).115,TABLE 57 GLOBAL ROTAVIRUS VACCINE SALES,BY,MANUFACTURER,2008($MILLIONS/%).115CHAPTER EIGHT:PARASITIC INFECTIOUS DISEASE.116CAUSES OF PARASITIC DISEASE.116MALARIA.116,TABLE 58 PROJECTED GLOBAL REVENUES FOR MALARIALPREVENTION AND TREATMENT MEASURES,THROUGH 2014($,MILLIONS).117,CAUSES OF MALARIA.118MALARIAL TREATMENTS.118TABLE 59 AVAILABLE DRUGS FOR THE TREATMENT OF MALARIA,2009.118,Current Treatments.119TABLE 60 PROJECTED GLOBAL REVENUE FROM MALARIAL,TREATMENTS,THROUGH 2014($MILLIONS).119,Evolving Treatments.119,GlaxoSmithKline.120Novartis.120Pfizer.120Sanofi-aventis.120Sigma-Tau.120MOSQUITO NETTING.120TABLE 61 MOSQUITO NETTING DISTRIBUTED,2006-2008.121TABLE 62 PROJECTED